CLINICAL TRIALS PROFILE FOR BENADRYL

All Clinical Trials for BENADRYL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00011804 ↗	Topiramate in the Treatment of Sciatica	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	2001-02-01	This study will test the effectiveness of topiramate to treat pain caused by lumbar radiculopathy, or sciatica. Sciatica results from damage to the lumbar nerve roots, typically causing back pain and sharp, shooting pain down one or both legs. Although sciatica is common, there are no good treatments for it. Topiramate belongs to a group of medications commonly used to treat pain caused by nerve damage. Patients between 18 and 75 years of age who have had sciatica pain daily for at least 3 months may be eligible for this study. (This is taken from the first paragraph of the Qualification Criteria in the consent form. The inclusion criteria on page 6 of the protocol say "low back pain of 3 months duration or longer present at least 5 out of 7 days a week" and signs and symptoms of lumbar radiculopathy. Which is correct?) Participants will provide a medical history, as well as occupational and social information. They will undergo a standard neurological examination, including a test of cognitive (thinking) abilities, muscular function, reflexes and a sensory examination. The latter involves testing with a pin placed on the surface of the skin. Participants will also have routine blood tests and will fill out questionnaires on their daily functioning and psychological well being. Additional procedures may include magnetic resonance imaging (MRI) scans and possible referral to a psychiatrist for evaluation of depression or emotional difficulties. This "cross-over" study consists of two parts. In one part, patients will receive topiramate and in the other, an active placebo. An active placebo is a drug that does not work for the problem being studied but whose side effects are like those of the test drug. Diphenhydramine (Benadryl) is the active placebo used in this study. Diphenhydramine is an allergy medication with very mild side effects, such as drowsiness. During both parts of the study-topiramate and placebo-patients will keep a daily log in which they rate their pain, record other procedures they undergo, such as injections and manipulations, and record medication side effects. In the first week of the study, patients will remain on their current medications and record pain levels once a day. After the first week, they will begin taking the study drugs-either topiramate in increasing doses ranging from 50 to 400 mg. or diphenhydramine in doses ranging from 6.25 to 50 mg. The drug doses will be increased gradually over 4 weeks to minimize possible side effects. Increases will continue until the maximum tolerated dose is reached. Patients will continue on the highest tolerated dose for two weeks and then be tapered off gradually over 12 days. They will remain off drugs completely for a 2-day washout period and then begin the next treatment. Those who took topiramate for the first part will take diphenhydramine for the second part and vice versa. A study nurse will call patients twice a week throughout the study to check for problems and answer questions. A physician will see patients 6 weeks after the start of each treatment. During the last visit, at the end of the study, patients will repeat the questionnaires they filled out at the beginning of the study. Patients and their doctors will be informed of the medications that were effective in each individual's care.
NCT00030992 ↗	BMS 247550 to Treat Kidney Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2002-02-01	This study will examine whether the experimental drug BMS 247550 (Ixabepilone) is an effective treatment for kidney cancer. BMS 247550 belongs to a class of drugs called epothilones that interfere with the ability of cancer cells to divide. In the way they kill cells, they are very similar to a class of compounds known as the taxanes, which include the drug Taxol. Other characteristics of the epothilones, however, enable them to work in cells that are resistant to Taxol. Patients 18 years of age or older with kidney cancer that has not spread to the central nervous system (unless the brain tumor has remained stable for at least six months after surgical or radiation treatment) may be eligible for this study. Pregnant or nursing women may not participate. Candidates are screened with various tests that may include blood and urine tests, electrocardiogram (EKG), and chest x-ray. Computerized tomography (CT) scans or X-rays, and possibly nuclear medicine studies may be done to determine the extent of disease. Participants receive BMS 247550 by a 1-hour infusion into a vein for 5 consecutive days (days 1, 2, 3, 4 and 5) of each 21-day treatment cycle. Patients must stay in the National Institutes of Health (NIH) area near Bethesda, Maryland, for 7 to 8 days during the first treatment cycle and for the 5 days of treatment in subsequent cycles. The total number of cycles will vary among patients, depending on their individual clinical situation. The drug dose may be increased gradually in subsequent cycles in patients who can tolerate such increases. In addition, participants undergo the following tests and procedures: - Periodic physical examinations and frequent blood tests - X-ray and other imaging studies to determine if the tumor is responding to the treatment. - Tumor biopsies to confirm the diagnosis or spread of tumor and to examine the reaction of certain proteins in cancer cells to BMS 247550. Two biopsies will be done. For this procedure, a small piece of tumor tissue is withdrawn through a needle under local anesthetic. Treatment will be stopped in patients whose tumor grows while receiving BMS 247550. Patients whose tumor disappears completely will be followed at NIH periodically for examinations and tests. Patients whose disease does not completely resolve or whose disease recurs may be advised of other appropriate research protocols at NIH or, if none are available, will be returned to the care of their local doctor.
NCT00038402 ↗	Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer	Completed	Genentech, Inc.	Phase 3	2001-04-01	The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods.
NCT00038402 ↗	Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer	Completed	M.D. Anderson Cancer Center	Phase 3	2001-04-01	The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods.
NCT00038623 ↗	Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma	Completed	Biogen	Phase 2	2002-04-01	Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed & Refractory Mantle Cell Lymphoma
NCT00038623 ↗	Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	2002-04-01	Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed & Refractory Mantle Cell Lymphoma
NCT00038844 ↗	Safety and Efficacy of Campath in Nonmyeloablative Transplantation	Completed	M.D. Anderson Cancer Center	N/A	2001-06-01	Objective of the low-dose transplant regimen must produce the following effects: 1. Suppression of the patient's immune system to prevent rejection of the donor cells; 2. Control of the lymphoma. The pretransplant regimen must suppress the lymphoma sufficiently to prevent marked progression of the tumor and allow time for the GVT effect to occur.

Clinical Trial Conditions for BENADRYL

Condition Name

Condition Name for BENADRYL
Intervention	Trials
Leukemia	19
Lymphoma	14
Chronic Lymphocytic Leukemia	9
Headache	6

Condition MeSH

Condition MeSH for BENADRYL
Intervention	Trials
Leukemia	28
Lymphoma	23
Leukemia, Lymphoid	21
Leukemia, Lymphocytic, Chronic, B-Cell	16

Clinical Trial Locations for BENADRYL

Trials by Country

Trials by Country for BENADRYL
Location	Trials
United States	196
Canada	11
Taiwan	1
Puerto Rico	1
China	1

Trials by US State

Trials by US State for BENADRYL
Location	Trials
Texas	75
California	15
New York	11
Maryland	11
Massachusetts	9

Clinical Trial Progress for BENADRYL

Clinical Trial Phase

Clinical Trial Phase for BENADRYL
Clinical Trial Phase	Trials
Phase 4	15
Phase 3	11
Phase 2	72

Clinical Trial Status

Clinical Trial Status for BENADRYL
Clinical Trial Phase	Trials
Completed	86
Recruiting	26
Terminated	26

Clinical Trial Sponsors for BENADRYL

Sponsor Name

Sponsor Name for BENADRYL
Sponsor	Trials
M.D. Anderson Cancer Center	58
National Cancer Institute (NCI)	16
Baylor College of Medicine	13

Sponsor Type

Sponsor Type for BENADRYL
Sponsor	Trials
Other	212
Industry	65
NIH	29

Clinical Trials Update, Market Analysis, and Projection for Benadryl (Diphenhydramine)

Last updated: October 28, 2025

---

Introduction

Benadryl, the brand name for diphenhydramine, remains a leading antihistamine medication broadly utilized for allergic reactions, sleep aid, and cold symptoms. With a long history dating back to the 1940s, Benadryl's familiarity has cemented its position in both OTC markets and healthcare settings. Nevertheless, the evolving regulatory landscape, advancing therapeutic alternatives, and shifting consumer preferences necessitate ongoing market and clinical insights. This report synthesizes recent clinical trial updates, market dynamics, and future projections for diphenhydramine, offering actionable intelligence for stakeholders.

---

Clinical Trials Update for Diphenhydramine

Despite its established safety profile, diphenhydramine continues to undergo research aimed at expanding its therapeutic scope and optimizing safety. Recent clinical investigations focus on novel applications, adverse effect mitigation, and comparative effectiveness.

Ongoing and Recent Clinical Trials

• Sleep Disorder Applications
  Multiple studies are assessing diphenhydramine’s efficacy and safety as an over-the-counter sedative for insomnia. A 2022 randomized controlled trial (RCT) published in Sleep Medicine Reviews examined its short-term use and found reasonable efficacy with manageable side effects when used intermittently [1]. However, concerns over cognitive impairment and anticholinergic burden are ongoing.

• Allergic and Rhinitic Conditions
  New studies compare diphenhydramine to second-generation antihistamines (cetirizine, loratadine). Results show faster onset of relief but higher sedation profiles, limiting long-term use in certain populations, especially the elderly.

• Adverse Effects and Safety Profiling
  Observational studies continue to monitor anticholinergic side effects, particularly cognitive decline in elderly users. A 2023 cohort study indicated increased risk for dementia with prolonged use, reinforcing current cautionary guidelines [2].

• Novel Formulations and Delivery Methods
  Trials exploring fast-dissolving tablets and combination therapies aim to improve adherence and reduce side effects. For example, studies are evaluating formulations that deliver diphenhydramine with fewer central nervous system depressant effects.

Regulatory and Labeling Developments

FDA and EMA review processes remain vigilant, particularly concerning anticholinergic risks. In 2022, the FDA issued updated labeling emphasizing cautious use in elderly populations due to cognitive risks. These regulatory shifts influence clinical trial designs and product marketing.

---

Market Analysis

Historical Market Dynamics

Benadryl’s global market value has historically been robust, driven by its OTC status and versatility. The US remains the largest market, accounting for approximately 60% of sales, with Europe and Asia-Pacific showing steady, growing demand.

Current Market Trends

• Demographic Shifts
  The aging populations in developed countries heighten awareness of anticholinergic cognitive risks, prompting some consumers and clinicians to favor second-generation antihistamines with fewer sedative and cognitive side effects. This trend impacts Benadryl's OTC sales, particularly among seniors.

• Evolving Consumer Preferences
  Consumers increasingly prefer non-sedating or "allergy-specific" medications, slightly impacting diphenhydramine sales. However, its affordability and efficacy in emergency antihistamine use sustain demand.

• Competitive Landscape
  The market faces competition from newer antihistamines (levocetirizine, fexofenadine), which offer similar efficacy with fewer side effects. These alternatives command premium pricing but face resistance due to brand loyalty and OTC familiarity with Benadryl.

• Regulatory and Labeling Influences
  Heightened regulatory scrutiny leads to stricter OTC labeling, affecting sales volume and marketing strategies. Companies are exploring prescription status for high-dose formulations due to safety concerns, which could shift market share toward pharmaceutical brands.

Market Projections

Based on current trends, the global antihistamine market is projected to grow at a compound annual growth rate (CAGR) of approximately 4.3% from 2023 to 2030 [3]. However, Benadryl’s relative market share is anticipated to slightly decline, owing to the shift toward second-generation antihistamines and safety profiles.

By 2030, the US OTC diphenhydramine market may decrease by approximately 10-15% from its peak, although value retention persists due to high demand for emergency and sleep aid formulations. Niche applications, such as circadian rhythm regulation and sleep aid in specific populations, may sustain residual sales.

---

Future Outlook and Strategic Considerations

Innovative Therapeutic Development

• Refined Formulations
  Advancing formulations that minimize anticholinergic side effects could extend Benadryl's market life, especially if combined with targeted delivery mechanisms or reduced dosing strategies.

• Combination Therapies
  Developing combination OTC products with non-sedating antihistamines or adjuncts may capture consumer interest, particularly for allergy sufferers seeking multi-symptom relief without cognitive impairment.

• Digital and Personalized Medicine
  Integrating digital tools to guide safe usage, particularly among vulnerable populations, can mitigate risks and enhance consumer confidence.

Regulatory Navigation

Manufacturers must stay abreast of evolving regulations, particularly against the backdrop of safety concerns. Potential shifts toward prescription-only status for higher doses could reconfigure market positioning, emphasizing the need for strategic licensing and formulation adaptations.

Market Opportunities

Emerging markets in Asia-Pacific and Latin America present growth opportunities, especially as urbanization fuels allergy and respiratory conditions. Tailoring formulations to local preferences and regulatory standards can foster expansion.

---

Key Takeaways

• Clinical developments indicate ongoing research into diphenhydramine’s expanded use, with safety concerns—particularly cognitive effects in the elderly—prompting regulatory caution and label updates.

• Market dynamics reflect a gradual shift away from sedating antihistamines among certain populations due to safety perceptions, favoring second-generation antihistamines. Nonetheless, Benadryl maintains a substantial market share driven by affordability and familiarity.

• Future projections suggest a plateauing or declining OTC market share for Benadryl in developed countries, but niche applications, emerging formulations, and expanding markets offer growth avenues.

• Strategic focus should be on developing safer formulations, leveraging combination therapies, and navigating regulatory landscapes to sustain relevance.

• Stakeholders must prioritize safety, consumer education, and innovation to navigate industry challenges effectively.

---

FAQs

1. Is Benadryl safe for long-term use?
   Prolonged use of Benadryl is generally discouraged, especially in elderly populations, due to its anticholinergic effects linked to cognitive impairment and increased dementia risk. Short-term use under medical guidance is considered safe.

2. Are there any ongoing efforts to develop safer alternatives to Benadryl?
   Yes. Research focuses on creating formulations with reduced anticholinergic burden, combining Benadryl with non-sedating agents, and developing targeted delivery systems to mitigate adverse effects.

3. How does Benadryl compare to second-generation antihistamines?
   Benadryl provides rapid relief but causes sedation and cognitive impairment in some users. Second-generation antihistamines like loratadine and cetirizine are non-sedating, safer for long-term use, and preferred for chronic allergy management.

4. What are the regulatory concerns associated with Benadryl?
   Regulatory agencies emphasize caution regarding sedative effects, especially in populations vulnerable to cognitive side effects. Labeling updates and potential move toward prescription status for specific formulations aim to ensure safe usage.

5. What markets offer growth opportunities for diphenhydramine products?
   Emerging markets in Asia-Pacific, Latin America, and Africa present growth potential due to increasing allergy-related health issues, urbanization, and expanding OTC distribution channels.

---

References

[1] Sleep Med Rev, 2022, "Efficacy and safety of diphenhydramine in short-term insomnia management."
[2] JAMA Neurol, 2023, "Anticholinergic medication use and dementia risk: A population-based cohort study."
[3] MarketsandMarkets, 2023, "Antihistamines Market by Product and Region."